ARG54310
anti-EpCAM antibody [VU-1D9] (APC)
anti-EpCAM antibody [VU-1D9] (APC) for Flow cytometry and Human
Controls and Markers antibody; Epithelial Marker antibody; Circulating Tumor Cells BioMarker antibody
Overview
| Product Description | APC-conjugated Mouse Monoclonal antibody [VU-1D9] recognizes CD326 / EpCAM |
|---|---|
| Tested Reactivity | Hu |
| Tested Application | FACS |
| Specificity | The clone VU-1D9 recognizes an epitope within EGF-like domain I of CD326 / EpCAM, a marker of epithelial lineages. This antibody strongly stains various normal epithelial cells and carcinomas. |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | VU-1D9 |
| Isotype | IgG1 |
| Target Name | EpCAM |
| Immunogen | Small cell lung carcinoma cell line H69. |
| Conjugation | APC |
| Alternate Names | MIC18; EGP; Tumor-associated calcium signal transducer 1; Epithelial glycoprotein 314; KSA; Ep-CAM; Epithelial cell surface antigen; Adenocarcinoma-associated antigen; HNPCC8; Cell surface glycoprotein Trop-1; EGP40; TACSTD1; KS1/4; hEGP314; Major gastrointestinal tumor-associated protein GA733-2; M4S1; MK-1; Epithelial glycoprotein; KS 1/4 antigen; ESA; DIAR5; EGP314; Epithelial cell adhesion molecule; EGP-2; TROP1; CD antigen CD326 |
Application Instructions
| Application Suggestion |
|
||||
|---|---|---|---|---|---|
| Application Note | * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
Properties
| Form | Liquid |
|---|---|
| Purification Note | The purified antibody is conjugated with cross-linked Allophycocyanin (APC) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary. |
| Buffer | PBS, 15 mM Sodium azide and 0.2% (w/v) high-grade protease free BSA |
| Preservative | 15 mM Sodium azide |
| Stabilizer | 0.2% (w/v) high-grade protease free BSA |
| Storage Instruction | Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Database Links | |
|---|---|
| Gene Symbol | EPCAM |
| Gene Full Name | epithelial cell adhesion molecule |
| Background | EpCAM is a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008] |
| Function | EpCAM may act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. [UniProt] |
| Research Area | Controls and Markers antibody; Epithelial Marker antibody; Circulating Tumor Cells BioMarker antibody |
| Calculated MW | 35 kDa |
| PTM | Hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability. |
Clone References
Superficial scrapings from breast tumors is a source for biobanking and research purposes.
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
FACS / Human
Differential gene expression in normal esophagus and Barrett's esophagus.
IHC / Human
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.
IHC / Human
EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder.
